Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Workshop on imaging science development for cancer prevention and preemption.

Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee.

Cancer Biomark. 2007;3(1):1-33.

PMID:
17655039
2.

Karyometry in the early detection and chemoprevention of intraepithelial lesions.

Ranger-Moore J, Alberts DS, Montironi R, Garcia F, Davis J, Frank D, Brewer M, Mariuzzi GM, Bartels HG, Bartels PH.

Eur J Cancer. 2005 Sep;41(13):1875-88.

PMID:
16087328
3.

Prevention of ovarian cancer: intraepithelial neoplasia.

Brewer MA, Johnson K, Follen M, Gershenson D, Bast R Jr.

Clin Cancer Res. 2003 Jan;9(1):20-30. Review.

4.

Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.

O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD.

Clin Cancer Res. 2002 Feb;8(2):314-46.

5.

[Imaging procedures in early cancer of the breast. Current status of screening and diagnosis].

Kessler M, Heywang-Köbrunner H, Westhaus R, Scheck R.

Chirurg. 1991 Feb;62(2):77-84. Review. German. No abstract available.

PMID:
2044426
7.

The convergent development of molecular-targeted drugs for cancer treatment and prevention.

Lippman SM, Heymach JV.

Clin Cancer Res. 2007 Jul 15;13(14):4035-41. Review.

8.

Surrogate end-point biomarkers in chemopreventive drug development.

Kelloff GJ, Sigman CC, Hawk ET, Johnson KM, Crowell JA, Guyton KZ.

IARC Sci Publ. 2001;154:13-26. Review.

PMID:
11220652
9.

Gastrointestinal cancer surveillance by optical sensing.

Bigio IJ, Singh SK.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4315-6. No abstract available.

10.

[Cytological method in the prevention and early diagnosis of cancer].

Iagubov AS, Agamova KA.

Feldsher Akush. 1988 Mar;53(3):32-6. Russian. No abstract available.

PMID:
2897938
11.

Optical markers in duodenal mucosa predict the presence of pancreatic cancer.

Liu Y, Brand RE, Turzhitsky V, Kim YL, Roy HK, Hasabou N, Sturgis C, Shah D, Hall C, Backman V.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4392-9.

12.

Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development.

Kelloff GJ, Sigman CC.

Nat Rev Cancer. 2007 Jul;7(7):508-18. Review.

PMID:
17568791
13.

Nanotechnology: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(19):1-43. Epub 2006 Nov 1.

14.

Interferons in precancer and cancer prevention: where are we?

Tanneberger S, Hrelia P.

J Interferon Cytokine Res. 1996 May;16(5):339-46. Review.

PMID:
8727073
15.

Development of cancer chemopreventive drugs based on mechanistic approaches.

Steele VE, Kelloff GJ.

Mutat Res. 2005 Dec 11;591(1-2):16-23. Epub 2005 Aug 3. Review.

PMID:
16083917
16.

Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.

Kelloff GJ, O'Shaughnessy JA, Gordon GB, Hawk ET, Sigman CC.

Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):593-6. No abstract available.

17.

Visualization and other emerging technologies as change makers for oral cancer prevention.

Rosin MP, Poh CF, Guillard M, Williams PM, Zhang L, MacaUlay C.

Ann N Y Acad Sci. 2007 Mar;1098:167-83. Epub 2007 Mar 1. Review.

PMID:
17332080
18.

[Problems in preventing oncological diseases].

Il'nitskiń≠ AP, Solov'ev IuN.

Sov Zdravookhr. 1984;(4):25-30. Russian. No abstract available.

PMID:
6729575
19.
20.

The Becton Dickinson FocalPoint GS Imaging System: clinical trials demonstrate significantly improved sensitivity for the detection of important cervical lesions.

Wilbur DC, Black-Schaffer WS, Luff RD, Abraham KP, Kemper C, Molina JT, Tench WD.

Am J Clin Pathol. 2009 Nov;132(5):767-75. doi: 10.1309/AJCP8VE7AWBZCVQT.

PMID:
19846820

Supplemental Content

Support Center